Testing BAT5906 vs Lucentis for diabetic vision swelling
Treatments studied
Part of Eyes & vision clinical trials.
This study compares two injectable medicines (BAT5906 and Lucentis) to treat diabetic macular edema—swelling in the back of the eye that blurs vision. Both drugs block a protein that causes abnormal blood vessel leakage, and this trial will show which works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 1 or type 2 diabetes and are 18–80 years old
- You have diabetic macular edema (swelling in the center of the retina) confirmed by eye imaging
- Your vision in the affected eye is between 20/40 and 20/400 on a standard eye chart
- Your other eye has better vision (at least 20/320) or can see well enough
- You haven't had eye injections with anti-VEGF drugs (like Avastin, Eylea, or Lucentis) in the past 3 months
- Your diabetes and blood pressure are reasonably controlled, and you have no active infections or serious heart/lung disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new eye drop or injection called ENN0403 for people with diabetic macular edema (swelling in the back of the eye due to diabetes). The goal is to see if it can improve vision and reduce swelling.
This trial tests an investigational drug called CU06-1004 for people with diabetic macular edema (swelling in the center of the retina caused by diabetes). It aims to see if the drug can improve vision and reduce swelling.
This study tests whether one eye injection (aflibercept) works better than another (bevacizumab) for people with diabetic macular edema. Both are already used for this condition, and the goal is to see which provides better vision improvement.
This trial compares a new treatment (EYP-1901, given as an injection) to a standard injection (aflibercept) for people with diabetic macular edema. It aims to see which works better at reducing swelling and improving vision.
This trial tests whether a substance called tauroursodeoxycholate (TUDCA) or a traditional Chinese medicine can help reduce swelling in the back of the eye caused by diabetes. It is for people with diabetic retinopathy and diabetic macular edema who have not had recent eye surgeries or changes in blood sugar or blood pressure control.
This phase 3 trial tests a new long-acting injection (EYP-1901) against a standard one (aflibercept) for people with diabetic macular edema. Both treatments are given as eye injections, and the goal is to see if the new drug works as well and may require fewer injections.
Hear when a new Diabetic Macular Edema (DME) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.